JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 21, 2003; DOI: 10.1124/jpet.103.057943


0022-3565/04/3083-846-856$20.00
JPET 308:846-856, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.057943v1
308/3/846    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auchampach, J. A.
Right arrow Articles by Gross, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auchampach, J. A.
Right arrow Articles by Gross, G. J.

CARDIOVASCULAR

Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

John A. Auchampach, Xiaowei Jin, Jeannine Moore, Tina C. Wan, Laura M. Kreckler, Zhi-Dong Ge, Jayashree Narayanan, Eric Whalley, William Kiesman, Barry Ticho, Glenn Smits, and Garrett J. Gross

Department of Pharmacology and Toxicology (J.A.A., J.M., T.C.W., L.M.K., Z.D.G., G.J.G.), Department of Physiology (J.N.), and the Cardiovascular Research Center (J.A.A., T.C.W., L.M.K., Z.D.G., J.N., G.J.G.), Medical College of Wisconsin, Milwaukee, Wisconsin; and Biogen Inc. (X.J., G.S., E.W., W. K., B.T.), Cambridge, Massachusetts

A1 adenosine receptor (AR) antagonists are effective diuretic agents that may be useful for treating fluid retention disorders including congestive heart failure. However, antagonism of A1ARs is potentially a concern when using these agents in patients with ischemic heart disease. To address this concern, the present study was designed to compare the actions of the A1AR antagonists CPX (1,3-dipropyl-8-cyclopentylxanthine), BG 9719 (1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthine), and BG 9928 (1,3-dipropyl-8-[1-(4-propionate)-bicyclo-[2,2,2]octyl]xanthine) on acute myocardial ischemia/reperfusion injury and ischemic preconditioning (IPC) in an in vivo dog model of infarction. Barbital-anesthetized dogs were subjected to 60 min of left anterior descending coronary artery occlusion followed by 3 h of reperfusion, after which infarct size was assessed by staining with triphenyltetrazolium chloride. IPC was elicited by four 5-min occlusion/5-min reperfusion cycles produced 10 min before the 60-min occlusion. Multiple-cycle IPC produced a robust reduction (~65%) in infarct size; this effect of IPC on infarct size was not abrogated in dogs pretreated with any of the three AR antagonists. Surprisingly, in the absence of IPC, pretreatment with CPX or BG 9928 before occlusion or immediately before reperfusion resulted in significant reductions (~40–50%) in myocardial infarct size. However, treatment with an equivalent dose of BG 9719 had no similar effect. We conclude that the A1AR antagonists BG 9719, BG 9928, and CPX do not exacerbate cardiac injury and do not interfere with IPC induced by multiple ischemia/reperfusion cycles. We discuss the possibility that the cardioprotective actions of CPX and BG 9928 may be related to antagonism of A2BARs.


Received August 22, 2003; accepted November 5, 2003.

Address correspondence to: Dr. John A. Auchampach, Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail: jauchamp{at}mcw.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Cappello, T. Angelone, B. Tota, P. Pagliaro, C. Penna, R. Rastaldo, A. Corti, G. Losano, and M. C. Cerra
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H719 - H727.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Eckle, T. Krahn, A. Grenz, D. Kohler, M. Mittelbronn, C. Ledent, M. A. Jacobson, H. Osswald, L. F. Thompson, K. Unertl, et al.
Cardioprotection by Ecto-5'-Nucleotidase (CD73) and A2B Adenosine Receptors
Circulation, March 27, 2007; 115(12): 1581 - 1590.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. D. Lasley, G. Kristo, B. J. Keith, and R. M. Mentzer Jr.
The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H426 - H431.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Willems, M. E. Reichelt, J. G. Molina, C.-X. Sun, J. L. Chunn, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick
Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts
Cardiovasc Res, July 1, 2006; 71(1): 79 - 87.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. R. Gross and G. J. Gross
Ligand triggers of classical preconditioning and postconditioning
Cardiovasc Res, May 1, 2006; 70(2): 212 - 221.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. R. Lankford, J.-N. Yang, R. Rose'Meyer, B. A. French, G. P. Matherne, B. B. Fredholm, and Z. Yang
Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning
Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1469 - H1473.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. E. Reichelt, L. Willems, J. G. Molina, C.-X. Sun, J. C. Noble, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick
Genetic Deletion of the A1 Adenosine Receptor Limits Myocardial Ischemic Tolerance
Circ. Res., February 18, 2005; 96(3): 363 - 367.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.